Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

NCT00114101 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00114101
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114101 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 15, 2004
Completion date
March 6, 2027
Enrollment
460 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

ds stage i multiple myeloma, ds stage ii multiple myeloma, ds stage iii multiple myeloma, refractory multiple myeloma, smoldering multiple myeloma